Kirn David sold $754K of FDMT
Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.92 ($12.92–$13.61, $0.75M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's $754K share sale may prompt short‑term price pressure, though it could be a pre‑planned liquidity event.
Market read
Primary insider sale provides fresh data for traders; limited broader market impact.
What to watch
The director may have tax or liquidity needs unrelated to company outlook.
Background
SEC Form 4 filing discloses an insider transaction for 4D Molecular Therapeutics (FDMT).
Ticker impact
Officer/director Kirn David sold 58,333 shares for $753,937 via a 10b5-1 plan on 2026-10-05.
likely pressure as the market prices in the insider sell.
The sale represents a $754K divestment by a director, which typically signals reduced confidence and can prompt short‑term selling.
Market effects
Minimal impact on the broader biotech sector; isolated insider activity.
Limited to US biotech investors; no broader regional effect.
Low; only relevant to traders tracking FDMT.
Counterpoint
The sale could be routine portfolio rebalancing under a 10b5-1 plan, not a bearish signal.
Key entities
- company4D Molecular Therapeutics, Inc.
US biotech company listed on NASDAQ under ticker FDMT.
- personKirn David
Officer and director of FDMT who executed the sale.
